Search Results - "Burris HA 3rd"

Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial.

Authors: Chen, Xinni Wang, Feng Cheng, Yuan et al.

Source: Clinical & Translational Discovery. Feb2026, Vol. 6 Issue 1, p1-11. 11p.

The evolving landscape of tissue-agnostic therapies in precision oncology.

Authors: Subbiah V Gouda MA Ryll B et al.

Source: CA: a cancer journal for clinicians [CA Cancer J Clin] 2024 Sep-Oct; Vol. 74 (5), pp. 433-452. Date of Electronic Publication: 2024 May 30.

Publication Type: Journal Article; Review; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0370647 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-4863 (Electronic) Linking ISSN: 00079235 NLM ISO Abbreviation: CA Cancer J Clin Subsets: MEDLINE

Interstitial Lung Disease Associated with Agaricus blazei Murill in a Patient with Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine-Based Therapy.

Authors: Iwai, Naoto Okuda, Takashi Sawada, Ryo et al.

Source: Case Reports in Gastroenterology. 2022, Vol. 16 Issue 1, p229-234. 6p.

Comparing Immunotherapy Versus Chemotherapy Alone as Second-Line Therapy for Malignant Tumors of the Biliary Tract: A Retrospective Study.

Authors: Jiang, Chengzhi Yang, Liu Kong, Ling Yang et al.

Source: Clinical Medicine Insights: Oncology. 2/16/2025, p1-9. 9p.

Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study.

Authors: Aseafan, Mohamed Alfakeeh, Ali H. Tashkandi, Emad et al.

Source: BMC Cancer. 1/3/2025, Vol. 25 Issue 1, p1-9. 9p.

Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting.

Authors: Wang, Qianqian Lv, Nan Xu, Dong et al.

Source: BMC Cancer. 7/24/2025, Vol. 25 Issue 1, p1-11. 11p.

Excavatolide C has oxidative-stress-dependent antiproliferative and apoptotic effects against breast cancer cells.

Authors: Shiau, Jun-Ping Yang, Che-Wei Liu, Wangta et al.

Source: BMC Cancer. 7/1/2025, Vol. 25 Issue 1, p1-12. 12p.

This result is not displayed to guests.
Login for full access.

HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.

Authors: Cigliano, Antonio Gigante, Isabella Serra, Marina et al.

Source: Journal of Experimental & Clinical Cancer Research (17569966). 9/6/2024, Vol. 43 Issue 1, p1-17. 17p.

Comparative inhibitory effects of zeolite, sepiolite, and kaolinite on A549 lung cancer cells.

Authors: Shamsabad, Fariba Nemati Salehi, Mohammad Hassan Shams, Jalaleddin et al.

Source: PLoS ONE. 2/11/2026, Vol. 21 Issue 2, p1-17. 17p.

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.

Authors: Oh DY He AR Bouattour M et al.

Source: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2024 Aug; Vol. 9 (8), pp. 694-704. Date of Electronic Publication: 2024 May 29.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-1253 (Electronic) NLM ISO Abbreviation: Lancet Gastroenterol Hepatol Subsets: MEDLINE

A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer.

Authors: Calheiros, Juliana Silva, Rita Barbosa, Filipa et al.

Source: Journal of Experimental & Clinical Cancer Research (17569966). 4/24/2025, Vol. 44 Issue 1, p1-29. 29p.

HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer.

Authors: Lin, Ting-I Tseng, Yi-Ru Dong, Min-Jyun et al.

Source: Clinical Epigenetics. 2/26/2025, Vol. 17 Issue 1, p1-14. 14p.

Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization.

Authors: Akram F Zainab S Shabbir I et al.

Source: Folia microbiologica [Folia Microbiol (Praha)] 2026 May 27. Date of Electronic Publication: 2026 May 27.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 0376757 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1874-9356 (Electronic) Linking ISSN: 00155632 NLM ISO Abbreviation: Folia Microbiol (Praha) Subsets: MEDLINE

Is the risk of brain metastasis and prognosis different in HER2-low breast cancer?

Authors: Culha Y Ünlü B Davarcı SE et al.

Source: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2026 May; Vol. 28 (5), pp. 1624-1636. Date of Electronic Publication: 2025 Nov 12.

Publication Type: Journal Article

Journal Info: Publisher: Springer Italia Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE; In Process

Contributions of Low-frequency-mutated Genes in Pancreatic Tumorigenesis and Their Implications in Precision Cancer Therapy.

Authors: Hsu, Shih-Han Kuo, Tzu-Lei Hsu, Ming-Chuan et al.

Source: Journal of Cancer Research & Practice. Jan-Mar2025, Vol. 12 Issue 1, p1-5. 5p.

Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis.

Authors: Tang, Jiayi Wang, Tianlei Wu, Hongwei et al.

Source: BMC Cancer. 11/5/2024, Vol. 24 Issue 1, p1-13. 13p.

Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumour with an NF1 Mutation Responding to Trametinib: A Case Report.

Authors: Hitchen, Nadia Cross, Matthew Laking, George et al.

Source: Case Reports in Oncology. 2023, Vol. 16 Issue 1, p1-6. 6p.

Study Protocol for a Trial: A Single-Arm, Open-Labeled Study Evaluating Transcatheter Arterial Embolization Plus Everolimus Combination Therapy for Patients With Liver Metastasis of Gastroenteropancreatic Neuroendocrine Tumors.

Authors: Takeuchi, Yasuto Kato, Hironari Horiguchi, Shigeru et al.

Source: Clinical Medicine Insights: Oncology. 11/6/2022, p1-5. 5p.

Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.

Authors: Hitchen, Nadia Waldron, Nick R. Deva, Sanjeev et al.

Source: Asia Pacific Journal of Clinical Oncology. Oct2023, Vol. 19 Issue 5, pe231-e238. 8p.